Skip to main content

Targeting novel lipid pathways for treatment of cardiovascular disease

Objective

Lipid lowering has significantly reduced cardiovascular disease (CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux builds on FP7-generated large-scale lipidomics data showing that specific sphingolipids and in particular distinct ceramides with specific acyl chain lengths are better predictors of CV outcome than traditional risk factors such as low-density lipoprotein-cholesterol. Sphingolipids are implicated in significant biological activities including cell survival, inflammation, and metabolic diseases. Moreover, their levels in metabolic diseases are modulated by previously unrecognized factors such as the gut microflora. Thus, we hypothesize that by controlling sphingolipid metabolism a better primary and secondary prevention of CVD events than with statins alone can be achieved. Athero-Flux builds on cutting-edge SME-led biotechnological tools including: a) high-throughput lipidomic platforms that allow the study of kinetics of lipid metabolism at the molecular lipid level including the new stable isotope labelling technique (Flux); b) whole genome RNA interference screening tools that will allow to identify the regulators of the production of ceramides and the mediators of their biological effect; c) unique locked nucleotide antagonist platforms that have been successfully used clinically in more that 300 patients worldwide. Moreover, it involves Academic partners with top expertise in atherosclerosis, sphingolipid metabolism, and gut microflora to validate targets in the ceramide metabolism. The identification and the validation of the best targets to abate ceramide metabolism though a combination of SME-based leading technology and academia modeling has a strong potential for development of new lipid lowering therapeutics to abate previously unrecognized risk factors for CVD.

Field of science

  • /natural sciences/biological sciences/genetics and heredity/nucleotide
  • /social sciences/sociology/demography/mortality
  • /natural sciences/biological sciences/genetics and heredity/genome
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases/arteriosclerosis

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Address
Wellington Square University Offices
OX1 2JD Oxford
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 126 019,44
Administrative Contact
Stephen Conway (Dr.)

Participants (11)

ZORA BIOSCIENCES OY
Finland
EU contribution
€ 973 250
Address
Tietotie 2 C
02150 Espoo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Riikka Katainen (Ms.)
CENIX BIOSCIENCE GMBH

Participation ended

Germany
EU contribution
€ 89 361,82
Address
Tatzberg 47
01307 Dresden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Karen Huppertz (Mrs.)
ROCHE INNOVATION CENTER COPENHAGEN AS
Denmark
EU contribution
€ 516 750
Address
Fremtidsvej 3
2970 Horsholm
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Henrik ørum (Dr.)
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU contribution
€ 583 500
Address
Soranou Efesiou 4
115 27 Athina
Activity type
Research Organisations
Administrative Contact
Dimitris Raptis (Mr.)
PIRKANMAA HOSPITAL DISTRICT
Finland
EU contribution
€ 531 000
Address
Teiskontie 35
33521 Tampere
Activity type
Research Organisations
Administrative Contact
Leena Käppi (Mrs.)
INSTITUT PASTEUR
France
EU contribution
€ 433 500
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
Administrative Contact
Marie-Laure Rosso (Dr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 456 000
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Caroline Hamilton (Mrs.)
SYDDANSK UNIVERSITET
Denmark
EU contribution
€ 320 000
Address
Campusvej 55
5230 Odense M
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Lone Ladegaard Laursen (Mrs.)
WEIZMANN INSTITUTE OF SCIENCE
Israel
EU contribution
€ 315 800
Address
Herzl Street 234
7610001 Rehovot
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Talia Tzahor (Ms.)
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Italy
EU contribution
€ 170 000
Address
Via Fiorentina 151
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Cristiana Tozzi (Dr.)
SITOOLS BIOTECH GMBH
Germany
EU contribution
€ 472 518,74
Address
Lochhamerstrasse 29A
82152 Planegg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Hannus (Dr.)